Chanticleer Holdings, Inc. (HOTR)
(Delayed Data from NSDQ)
$2.10 USD
-0.14 (-6.25%)
Updated Nov 13, 2017 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Sonnet BioTherapeutics Holdings, Inc. [HOTR]
Reports for Purchase
Showing records 1 - 15 ( 15 total )
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
ValuEngine Detailed Valuation Report for HOTR
Provider: ValuEngine, Inc
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
Dropping coverage due to termination of research services.
Provider: Taglich Brothers, Inc.
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
Maintaining Speculative Buy rating, but reducing our 12-month price target to $1.95 per share from $2.10 due to diminished sector valuation
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
Maintaining Speculative Buy rating, but reducing our 12-month price target.
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
At the end of 2Q15, the company had 47 restaurants and was operating at an annualized
Provider: SEETHRUEQUITY, LLC
Analyst: TANDON A
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
Recent results show continued growth, power in burger concept
Provider: SEETHRUEQUITY, LLC
Analyst: TANDON A
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
We are maintaining our Speculative Buy rating and 12-month price target of $4.65 per share
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
We are maintaining our Speculative Buy rating but decreasing our 12-month price target to $4.65 per share from $5.80
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
Maintaining Speculative Buy rating and increasing our 12-month price target to $5.80 per share from $4.95 due to increased sector valuation
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
Maintaining Speculative Buy rating and $4.95 per share (12-month) price target.
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
We are maintaining our price target for Chanticleer at this time.
Provider: SEETHRUEQUITY, LLC
Analyst: TANDON A
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
Initiated with Speculative Buy rating with a (12-month) price target of $4.95 per share.
Provider: Taglich Brothers, Inc.
Analyst: HALPERN H
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
Company: Sonnet BioTherapeutics Holdings, Inc.
Industry: Retail - Restaurants
We initiate coverage with a price target of $4.00 per share
Provider: SEETHRUEQUITY, LLC
Analyst: TANDON A
|